Calyxt Inc (NASDAQ:CLXT) CEO James Blome sold 4,140 shares of Calyxt stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $5.59, for a total transaction of $23,142.60. Following the sale, the chief executive officer now directly owns 190,422 shares of the company’s stock, valued at approximately $1,064,458.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
NASDAQ CLXT traded up $0.19 on Thursday, reaching $5.68. The company had a trading volume of 66,010 shares, compared to its average volume of 107,672. The firm has a market capitalization of $182.18 million, a price-to-earnings ratio of -4.18 and a beta of 2.35. The company has a debt-to-equity ratio of 0.45, a quick ratio of 8.29 and a current ratio of 9.43. Calyxt Inc has a 1-year low of $2.40 and a 1-year high of $8.41. The company’s fifty day moving average is $5.95 and its 200-day moving average is $4.76.
Calyxt (NASDAQ:CLXT) last announced its earnings results on Wednesday, August 5th. The company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.03. The firm had revenue of $2.31 million during the quarter. Calyxt had a negative net margin of 392.49% and a negative return on equity of 77.67%. On average, research analysts forecast that Calyxt Inc will post -1.24 earnings per share for the current year.
Several equities analysts have recently issued reports on the stock. National Securities lowered shares of Calyxt from a “buy” rating to a “neutral” rating in a report on Thursday, August 13th. Zacks Investment Research lowered shares of Calyxt from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Finally, Canaccord Genuity assumed coverage on shares of Calyxt in a report on Tuesday, July 28th. They issued a “buy” rating and a $8.00 price target for the company. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $6.88.
Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.